Market Pulse
The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around the world. It is truly a save-the-world moment for the drug industry, an industry that has been widely despised and consistently polls towards the bottom, even below the Federal Government, in reputation surveys. But healthcare now faces an opportunity to do good against a common viral enemy